Repligen Reports Record Q3 Revenue and Strategic Expansion into Cell Therapy
Repligen (RGEN) reported record third-quarter revenue of $209 million, driven by a recovery in bioprocessing demand. Despite a decline in capital equipment revenue, the company achieved its highest level of new orders in five years, with mid-teens percentage year-over-year growth, building a significant backlog for 2027. The company is strategically pivoting toward high-growth sectors through the acquisition of BioLife, which is expected to contribute $24 million in revenue in the fourth quarter. Additionally, Repligen has successfully expanded its service contracts by nearly 40% year-to-date, creating a more stable base of recurring revenue through maintenance and technical services.
Tickers: $RGEN
Topics: bioprocessing equipment capital equipment orders cell therapy revenue growth
Read the full article at Motley Fool
Part of the story Big Digital Reports Q3 2026 Revenue Growth and Strategic Expansion via Hood County Acquisition (8 articles)